Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Prostatic Neoplasms 7Lymphoma 5Burkitt Lymphoma 5Neoplasms 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Lymphoma, Follicular 3Hodgkin Disease 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Metastatic Castration-resistant Prostate Cancer 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Leukemia 2Endometrial Neoplasms 2Down Syndrome 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Neoplasm Metastasis 1Myasthenia Gravis 1Lymphoma, T-Cell, Peripheral 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Immunoblastic Lymphadenopathy 1Heart Failure 1Enteropathy-Associated T-Cell Lymphoma 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Cyclophosphamide 4Prednisone 3Etoposide 3Doxorubicin 3etoposide phosphate 2Vincristine 2Brentuximab Vedotin 2tazemetostat 1prednylidene 1pembrolizumab 1fludarabine 1duvelisib 1deltacortene 1Prednisolone 1Melphalan 1Cytarabine 1Cholecalciferol 1Carmustine 1Azacitidine 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enteropathy-Associated T-Cell Lymphoma × Prednisolone × 1 year × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡